Immunome doses first patient in Phase 1 trial of FAP-targeted therapy
Tweet Send to a Friend
Immunome, Inc. (Nasdaq: IMNM) announced that the first patient has been dosed in a Phase 1, first-in-human trial of IM-3050 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
